Payment overview · 2025
General Payments
$34,647.10
302 reported records · 32 companies
Healthcare provider profile · identity verified
Mark S Box, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · KANSAS CITY, MO · NPI 1477604817
Verified facts
What the public records show
CMS Open Payments records show Mark S Box, MD received $34,647.10 in general payments during 2025 across 302 reported records.
ABBVIE INC. accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rinvoq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Benlysta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $9,028.55 | 26.1% | 58 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $7,545.30 | 21.8% | 16 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $6,999.07 | 20.2% | 21 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $4,200.86 | 12.1% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $3,422.82 | 9.9% | 66 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $482.52 | 1.4% | 20 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $436.60 | 1.3% | 17 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $434.36 | 1.2% | 13 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $248.59 | 0.7% | 8 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $236.82 | 0.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $210.37 | 0.6% | 8 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $197.73 | 0.6% | 10 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $165.67 | 0.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.84 | 0.4% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.26 | 0.3% | 5 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $97.81 | 0.3% | 1 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $93.41 | 0.3% | 5 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $88.42 | 0.3% | 5 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $86.52 | 0.2% | 3 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $66.37 | 0.2% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $57.17 | 0.2% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $53.89 | 0.2% | 4 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $53.35 | 0.1% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $49.86 | 0.1% | 3 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $33.00 | 0.1% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.58 | 0.1% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $19.53 | 0.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.35 | 0.1% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $17.81 | 0.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.57 | 0.1% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $15.57 | 0.0% | 1 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $14.53 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,800.00 | 13 |
| Consulting Fee | $7,937.50 | 2 |
| Food and Beverage | $6,283.37 | 275 |
| Travel and Lodging | $2,427.24 | 10 |
| Education | $198.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $7,558.14 | 39 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $7,427.15 | 14 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $4,200.86 | 17 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $2,721.72 | 19 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $1,475.14 | 20 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $600.03 | 15 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $427.76 | 19 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $401.83 | 36 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $367.98 | 16 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $248.59 | 8 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $236.82 | 3 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $211.06 | 11 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $197.73 | 10 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $152.66 | 4 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological, Drug | HOSPIRA, INC., Octapharma USA, Inc., PFIZER INC. | $129.11 | 7 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $125.84 | 2 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $125.02 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $110.90 | 4 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $108.26 | 5 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $104.13 | 5 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $66.37 | 1 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $59.88 | 4 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $57.17 | 3 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $53.89 | 4 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $53.89 | 4 | 2025 |
Source payment records
|
|||||
| Quzyttir Normalized: quzyttir |
Drug | TerSera Therapeutics LLC | $53.35 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC. | $50.40 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $49.86 | 3 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| Gazyva Normalized: gazyva |
Biological | Genentech USA, Inc. | $28.54 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| HYRIMOZ Normalized: hyrimoz |
Biological | Sandoz Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $14.37 | 2 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | HOSPIRA, INC. | $8.94 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $8.52 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $8.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 654 | 82 |
| Prednisone | Prednisone | 471 | 119 |
| Tramadol Hcl | Tramadol Hcl | 384 | 78 |
| Methotrexate | Methotrexate Sodium | 381 | 113 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 355 | 101 |
| Meloxicam | Meloxicam | 353 | 103 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 344 | 41 |
| Alprazolam | Alprazolam | 327 | 46 |
| Gabapentin | Gabapentin | 299 | 65 |
| Oxycodone Hcl | Oxycodone Hcl | 291 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 256 | 55 |
| Celecoxib | Celecoxib | 243 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 221 | 42 |
| Methylprednisolone | Methylprednisolone | 190 | 122 |
| Pregabalin | Pregabalin | 179 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 159 | 39 |
| Morphine Sulfate Er | Morphine Sulfate | 153 | 15 |
| Omeprazole | Omeprazole | 145 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 24 |
| Azathioprine | Azathioprine | 133 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 119 | 33 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 119 | 28 |
| Topiramate | Topiramate | 101 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 93 | 25 |
| Trazodone Hcl | Trazodone Hcl | 87 | 18 |
| Allopurinol | Allopurinol | 85 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 17 |
| Furosemide | Furosemide | 68 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 15 |
| Clonazepam | Clonazepam | 67 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 67 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 64 | 14 |
| Carisoprodol | Carisoprodol | 55 | suppressed |
| Leflunomide | Leflunomide | 53 | 19 |
| Lisinopril | Lisinopril | 51 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 14 |
| Alendronate Sodium | Alendronate Sodium | 49 | 18 |
| Losartan Potassium | Losartan Potassium | 49 | 12 |
| Potassium Chloride | Potassium Chloride | 49 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 12 |
| Oxycontin | Oxycodone Hcl | 47 | suppressed |
| Folic Acid | Folic Acid | 46 | 17 |
| Sulfasalazine | Sulfasalazine | 46 | 13 |
| Diazepam | Diazepam | 44 | suppressed |
| Etodolac | Etodolac | 44 | suppressed |
| Fentanyl | Fentanyl | 44 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 18 |
| Nabumetone | Nabumetone | 43 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 40 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 40 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Simvastatin | Simvastatin | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Methadone Hcl | Methadone Hcl | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Benlysta | Belimumab | 31 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 31 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 30 | suppressed |
| Metformin Hcl | Metformin Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 11 |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 28 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Humira(Cf) Pen | Adalimumab | 27 | suppressed |
| Enbrel Sureclick | Etanercept | 26 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 26 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | 11 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Orencia Clickject | Abatacept | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 14 |
| Dapsone | Dapsone | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 15 | suppressed |
| Enbrel Mini | Etanercept | 14 | suppressed |
| Rinvoq | Upadacitinib | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Lexapro | Escitalopram Oxalate | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Humira(Cf) | Adalimumab | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Restasis | Cyclosporine | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34,647.10 · 302 records | ABBVIE INC. | ACTHAR, Actemra, BENLYSTA, Bimzelx, COSENTYX, CRYSVITA, CUTAQUIG, EVENITY, Gazyva, HADLIMA, HYRIMOZ, JOURNAVX, KEVZARA, KRYSTEXXA, Leqembi, OCTAGAM IMMUNE GLOBULIN (HUMAN), OPSUMIT, OPSYNVI, ORENCIA, OTEZLA, PANZYGA, PEMGARDA, PURIFIED CORTROPHIN GEL, QULIPTA, Quzyttir, RENFLEXIS, RINVOQ, SAPHNELO, SIMPONI ARIA, SKYRIZI, STRENSIQ, TALTZ, TAVNEOS, TERIPARATIDE, TONMYA, TREMFYA, Tymlos, UBRELVY, UPLIZNA, UPTRAVI, XELJANZ | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error